Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

cipla usa inc. - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - treatment of cytomegalovirus (cmv) retinitis: valganciclovir is indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1)] . prevention of cmv disease: valganciclovir is indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies (14.1)] . prevention of cmv disease: valganciclovir is indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies (14.2)] . valganciclovir is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see adverse reactions (6.1)]. risk summary after oral administration, valganciclovir (prodrug) is conver

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

ajanta pharma usa inc. - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - treatment of cytomegalovirus (cmv) retinitis: valganciclovir tablets, usp are indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1)] . prevention of cmv disease: valganciclovir tablets, usp are indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies (14.1)] . prevention of cmv disease: valganciclovir tablets, usp are indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies (14.2)] . valganciclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see adverse reactions (6.1)]. risk summary after oral

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - ganciclovir (unii: p9g3ckz4p5) (ganciclovir - unii:p9g3ckz4p5) - ganciclovir 250 mg - ganciclovir capsules are indicated for the prevention of cmv disease in solid organ transplant recipients and in individuals with advanced hiv infection at risk for developing cmv disease. ganciclovir capsules are also indicated as an alternative to the intravenous formulation for maintenance treatment of cmv retinitis in immunocompromised patients, including patients with aids, in whom retinitis is stable following appropriate induction therapy and for whom the risk of more rapid progression is balanced by the benefit associated with avoiding daily iv infusions (see clinical trials ). safety and efficacy of ganciclovir have not been established for congenital or neonatal cmv disease; not for the treatment of established cmv disease other than retinitis; nor for use in non-immunocompromised individuals. the safety and efficacy of ganciclovir capsules have not been established for treating any manifestation of cmv disease other than maintenance treatment of cmv retinitis. ganciclovir is contraindicated in pati

Izrael - engleski - Ministry of Health

tzamal bio-pharma ltd - ganciclovir as sodium - powder for solution for infusion - ganciclovir as sodium 500 mg - ganciclovir - cymevene iv is indicated for the treatment of cmv retinitis in immunocompromised patiens, including patients with acquired immunodeficiency syndrome (aids). cymevene iv is also indicated for the prevention of cmv disease in transplant recipients at risk for cmv disease.

Izrael - engleski - Ministry of Health

a.l. medi-market ltd. - ganciclovir as sodium - powder for concentrate for solution for infusion - ganciclovir as sodium 500 mg/vial - ganciclovir - ganciclovir medi-market 500 mg is indicated for the treatment of cmv retinitis in immunocompromised patiens, including patients with acquired immunodeficiency syndrome (aids). ganciclovir medi-market 500 mg is also indicated for the prevention of cmv disease in transplant recipients at risk for cmv disease.

Kanada - engleski - Health Canada

fresenius kabi canada ltd - ganciclovir (ganciclovir sodium) - powder for solution - 500mg - ganciclovir (ganciclovir sodium) 500mg - nucleosides and nucleotides

Kanada - engleski - Health Canada

auro pharma inc - ganciclovir (ganciclovir sodium) - powder for solution - 500mg - ganciclovir (ganciclovir sodium) 500mg - nucleosides and nucleotides

Kanada - engleski - Health Canada

sterimax inc - ganciclovir (ganciclovir sodium) - powder for solution - 500mg - ganciclovir (ganciclovir sodium) 500mg - nucleosides and nucleotides

Kanada - engleski - Health Canada

formative pharma inc. - ganciclovir (ganciclovir sodium) - powder for solution - 500mg - ganciclovir (ganciclovir sodium) 500mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - valganciclovir hydrochloride - oral tablet - 450mg